Overview

Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)

Status:
Unknown status
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
This study aims to investigate the efficacy and safety of PET regimen combined with Chidamide for angioimmunoblastic T cell lymphoma patients.
Phase:
Phase 2
Details
Lead Sponsor:
Qingdao University
Treatments:
Etoposide
Etoposide phosphate
Prednisone
Thalidomide